miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer

Simple Summary Resistance to anti-HER2+ therapy remains the main clinical challenge in the management of the HER2+ breast cancer subtype. The objective of our study was to analyze the involvement of microRNAs in the resistance to trastuzumab. We identified miR-146a-5p as the major dysregulated microRNA among parental and trastuzumab-resistant HER2+ breast cancer cells. The gain- and loss-of-function of this miRNA modulates resistance to trastuzumab in vitro, and elevated levels of miR-146a-5p in the primary tumor have been associated with a poor prognosis. In addition, exosomes from trastuzumab-resistant cells contain high levels of miR-146a-5p, and may reduce the effect of trastuzumab on sensitive cancer cells, increasing the expression of epithelial-to-mesenchymal transition markers and the capacities for migration and angiogenesis. The results of this study demonstrate for the first time the involvement of miR-146a-5p in resistance to trastuzumab, and suggest that exosomes play an important role in this process. Abstract Trastuzumab treatment has significantly improved the prognosis of HER2-positive breast cancer patients. Despite this, resistance to therapy still remains the main clinical challenge. In order to evaluate the implication of microRNAs in the trastuzumab response, we performed a microRNA array in parental and acquired trastuzumab-resistant HER2-positive breast cancer cell lines. Our results identified miR-146a-5p as the main dysregulated microRNA. Interestingly, high miR-146a-5p expression in primary tumor tissue significantly correlated with shorter disease-free survival in HER2-positive breast cancer patients. The gain- and loss-of-function of miR-146a-5p modulated the response to trastuzumab. Furthermore, the overexpression of miR-146a-5p increased migration and angiogenesis, and promoted cell cycle progression by reducing CDKN1A expression. Exosomes from trastuzumab-resistant cells showed a high level of miR-146a-5p expression compared with the parental cells. In addition, the co-culture with resistant cells’ exosomes was able to decrease in sensitivity and increase the migration capacities in trastuzumab-sensitive cells, as well as angiogenesis in HUVEC-2 cells. Collectively, these data support the role of miR-146a-5p in resistance to trastuzumab, and demonstrate that it can be transferred by exosomes conferring resistance properties to other cells.

[1]  Jing Han,et al.  Exosome-mediated transfer of lncRNA-SNHG14 promotes trastuzumab chemoresistance in breast cancer , 2022, International journal of oncology.

[2]  P. Eroles,et al.  MicroRNAs as a clue to overcome breast cancer treatment resistance , 2021, Cancer metastasis reviews.

[3]  A. Lluch,et al.  Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer , 2021, Cancers.

[4]  P. P. Di Fiore,et al.  miR-146 connects stem cell identity with metabolism and pharmacological resistance in breast cancer , 2021, The Journal of cell biology.

[5]  A. Lluch,et al.  Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer , 2021, ESMO open.

[6]  A. Lluch,et al.  Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer , 2020, International journal of molecular sciences.

[7]  J. Xu,et al.  Epigenetic silencing of CDKN1A and CDKN2B by SNHG1 promotes the cell cycle, migration and epithelial-mesenchymal transition progression of hepatocellular carcinoma , 2020, Cell Death & Disease.

[8]  S. Kabekkodu,et al.  The emerging role of miRNA clusters in breast cancer progression. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[9]  W. Schiemann,et al.  Epithelial–Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance , 2020, Molecular Cancer Research.

[10]  Rong Wang,et al.  Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1 , 2020, Frontiers in Oncology.

[11]  F. Liu,et al.  Breast cancer-derived exosomes regulate cell invasion and metastasis in breast cancer via miR-146a to activate cancer associated fibroblasts in tumor microenvironment. , 2020, Experimental cell research.

[12]  K. Seong,et al.  The Emerging Roles of Exosomes as EMT Regulators in Cancer , 2020, Cells.

[13]  Yuanting Gu,et al.  Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation , 2020, Molecular Cancer.

[14]  Fan Zhang,et al.  Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer , 2020, Cell Death & Disease.

[15]  Chi-Hung Lin,et al.  RAB27B‐activated secretion of stem‐like tumor exosomes delivers the biomarker microRNA‐146a‐5p, which promotes tumorigenesis and associates with an immunosuppressive tumor microenvironment in colorectal cancer , 2019, International journal of cancer.

[16]  S. Noguchi,et al.  Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer , 2019, Breast Cancer Research.

[17]  B. Wang,et al.  Cisplatin-resistant MDA-MB-231 cell-derived exosomes increase the resistance of recipient cells in an exosomal miR-423-5p-dependent manner. , 2019, Current drug metabolism.

[18]  Chi Sun,et al.  Circulating Exosomes Derived-miR-146a from Systemic Lupus Erythematosus Patients Regulates Senescence of Mesenchymal Stem Cells , 2019, BioMed research international.

[19]  A. Seifalian,et al.  Emerging roles of exosomal miRNAs in breast cancer drug resistance , 2019, IUBMB life.

[20]  Cai Han,et al.  Noncoding RNAs in cancer therapy resistance and targeted drug development , 2019, Journal of Hematology & Oncology.

[21]  P. Mauri,et al.  Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin/trastuzumab-induced cardiac toxicity. , 2019, Cardiovascular research.

[22]  Dihua Yu,et al.  Exosomes in cancer development, metastasis, and immunity. , 2019, Biochimica et biophysica acta. Reviews on cancer.

[23]  Shaghayegh Haghjooy Javanmard,et al.  The expression level of hsa-miR-146a-5p in plasma-derived exosomes of patients with diffuse large B-cell lymphoma , 2019, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[24]  Xinping Luo,et al.  Exosomes derived from miR‐146a‐modified adipose‐derived stem cells attenuate acute myocardial infarction−induced myocardial damage via downregulation of early growth response factor 1 , 2018, Journal of cellular biochemistry.

[25]  L. O’Driscoll,et al.  Extracellular vesicles and anti-cancer drug resistance. , 2018, Biochimica et biophysica acta. Reviews on cancer.

[26]  Si-ying Zhou,et al.  Exosome: a novel mediator in drug resistance of cancer cells. , 2018, Epigenomics.

[27]  X. Zhu,et al.  Treatment effect of CDKN1A on rheumatoid arthritis by mediating proliferation and invasion of fibroblast‐like synoviocytes cells , 2018, Clinical and experimental immunology.

[28]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[29]  Wei-xian Chen,et al.  Analysis of miRNA signature differentially expressed in exosomes from adriamycin-resistant and parental human breast cancer cells , 2018, Bioscience reports.

[30]  J. Redón,et al.  Urinary exosome miR-146a is a potential marker of albuminuria in essential hypertension , 2018, Journal of Translational Medicine.

[31]  Yanping Zhang,et al.  Identification of miR-146a is Associated with the Aggressiveness and Suppresses Proliferation via Targeting CDKN2A in Breast Cancer , 2018, Pathology & Oncology Research.

[32]  Suping Han,et al.  miR-146a promotes cervical cancer cell viability via targeting IRAK1 and TRAF6. , 2018, Oncology reports.

[33]  R. Price,et al.  MicroRNA-146a Regulates Perfusion Recovery in Response to Arterial Occlusion via Arteriogenesis , 2018, Front. Bioeng. Biotechnol..

[34]  V. Brod,et al.  Function of miR-146a-5p in Tumor Cells As a Regulatory Switch between Cell Death and Angiogenesis: Macrophage Therapy Revisited , 2018, Front. Immunol..

[35]  M. Fabbri,et al.  Mechanisms of Drug Resistance in Cancer: The Role of Extracellular Vesicles , 2017, Proteomics.

[36]  T. Deguchi,et al.  Exosomes expressing carbonic anhydrase 9 promote angiogenesis. , 2017, Biochemical and biophysical research communications.

[37]  Zhiwei Wu,et al.  Exosome-mediated miR-146a transfer suppresses type I interferon response and facilitates EV71 infection , 2017, PLoS pathogens.

[38]  Ji-Young Hong,et al.  The role of exosomes and miRNAs in drug‐resistance of cancer cells , 2017, International journal of cancer.

[39]  W. Guo,et al.  Exosomes: New players in cancer , 2017, Oncology reports.

[40]  W. Wenyu,et al.  MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer. , 2017, European review for medical and pharmacological sciences.

[41]  B. Xiao,et al.  Immature Exosomes Derived from MicroRNA-146a Overexpressing Dendritic Cells Act as Antigen-Specific Therapy for Myasthenia Gravis , 2017, Inflammation.

[42]  L. Ding,et al.  Exosomal miR‐146a Contributes to the Enhanced Therapeutic Efficacy of Interleukin‐1β‐Primed Mesenchymal Stem Cells Against Sepsis , 2017, Stem cells.

[43]  M. Ashraf,et al.  Mesenchymal stem cells release exosomes that transfer miRNAs to endothelial cells and promote angiogenesis , 2017, Oncotarget.

[44]  Wen-Chao Liu,et al.  LPS induces HUVEC angiogenesis in vitro through miR-146a-mediated TGF-β1 inhibition. , 2017, American journal of translational research.

[45]  F. Rojo,et al.  The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene , 2017, Scientific Reports.

[46]  F. Rojo,et al.  Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines. , 2016, American journal of cancer research.

[47]  A. Lánczky,et al.  miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients , 2016, Breast Cancer Research and Treatment.

[48]  P. Reddy,et al.  Are circulating microRNAs peripheral biomarkers for Alzheimer's disease? , 2016, Biochimica et biophysica acta.

[49]  Yu-Chen Gu,et al.  MiR-146a-5p inhibits cell proliferation and cell cycle progression in NSCLC cell lines by targeting CCND1 and CCND2 , 2016, Oncotarget.

[50]  Si-ying Zhou,et al.  MiRNAs-mediated cisplatin resistance in breast cancer , 2016, Tumor Biology.

[51]  Michael E. Egger,et al.  Melanoma cell-derived exosomes promote epithelial-mesenchymal transition in primary melanocytes through paracrine/autocrine signaling in the tumor microenvironment. , 2016, Cancer letters.

[52]  Q. Han,et al.  Exosomes secreted by mesenchymal stem cells promote endothelial cell angiogenesis by transferring miR-125a , 2016, Journal of Cell Science.

[53]  A. Hata,et al.  Dysregulation of microRNA biogenesis machinery in cancer , 2016, Critical reviews in biochemistry and molecular biology.

[54]  L. Su,et al.  Up-regulation of FGFBP1 signaling contributes to miR-146a-induced angiogenesis in human umbilical vein endothelial cells , 2016, Scientific Reports.

[55]  Raghu Kalluri,et al.  The biology and function of exosomes in cancer. , 2016, The Journal of clinical investigation.

[56]  G. Hortobagyi,et al.  Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer , 2016, Oncotarget.

[57]  L. Sánchez-Lorenzo,et al.  Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It , 2016, Clinical Medicine Insights. Oncology.

[58]  R. Murali,et al.  Trastuzumab-Resistant Luminal B Breast Cancer Cells Show Basal-Like Cell Growth Features Through NF-κB-Activation. , 2016, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[59]  S. Zhong,et al.  Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs , 2015, Tumor Biology.

[60]  S. Zhong,et al.  Exosomes in development, metastasis and drug resistance of breast cancer , 2015, Cancer science.

[61]  Sha Li,et al.  Exosome and Exosomal MicroRNA: Trafficking, Sorting, and Function , 2015, Genom. Proteom. Bioinform..

[62]  A. Hölscher,et al.  Exosomal onco-miRs from serum of patients with adenocarcinoma of the esophagus: comparison of miRNA profiles of exosomes and matching tumor , 2015, Tumor Biology.

[63]  Wenting Liu,et al.  The role of exosomes and "exosomal shuttle microRNA" in tumorigenesis and drug resistance. , 2015, Cancer letters.

[64]  S. Zhong,et al.  Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs , 2014, Tumor Biology.

[65]  B. Bao,et al.  Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review , 2013, Cancer and Metastasis Reviews.

[66]  S. Raimondo,et al.  Exosomes as Intercellular Signaling Organelles Involved in Health and Disease: Basic Science and Clinical Applications , 2013, International journal of molecular sciences.

[67]  J. Rak,et al.  Extracellular Vesicles – Biomarkers and Effectors of the Cellular Interactome in Cancer , 2013, Front. Pharmacol..

[68]  E. López-Bonet,et al.  Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin) , 2012, Cell cycle.

[69]  Hongwei Zhang,et al.  Drug resistance-related microRNAs in esophageal cancer , 2012, Expert opinion on biological therapy.

[70]  F. Reyal,et al.  Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. , 2012, Cancer research.

[71]  R. Jain,et al.  Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases , 2012, Proceedings of the National Academy of Sciences.

[72]  C. Sotiriou,et al.  Beyond trastuzumab: new treatment options for HER2-positive breast cancer. , 2011, Breast.

[73]  G. Camussi,et al.  Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. , 2011, Cancer research.

[74]  J. Baselga,et al.  p95HER2 and breast cancer. , 2011, Cancer research.

[75]  S. Chandarlapaty,et al.  HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies , 2011, Expert review of anticancer therapy.

[76]  T. Mukohara.  Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer , 2011, Cancer science.

[77]  Andrey Golubov,et al.  Alterations of microRNAs and their targets are associated with acquired resistance of MCF‐7 breast cancer cells to cisplatin , 2010, International journal of cancer.

[78]  J. Baselga,et al.  Treatment of HER2-overexpressing breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[79]  Wanyi Tai,et al.  The role of HER2 in cancer therapy and targeted drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[80]  Johan Hansson,et al.  MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. , 2010, The Journal of investigative dermatology.

[81]  J. Engelman,et al.  H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation via heregulin production and activation of HER3 , 2010, Oncogene.

[82]  Xiaohua Li,et al.  Survival prediction of gastric cancer by a seven-microRNA signature , 2009, Gut.

[83]  C. Bamdad,et al.  MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells , 2009, Breast Cancer Research and Treatment.

[84]  Kedar S Vaidya,et al.  Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. , 2009, Cancer research.

[85]  Christophe Lemetre,et al.  MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer , 2009, Breast Cancer Research.

[86]  S. Schokrpur,et al.  Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells , 2008, Oncogene.

[87]  R. Rodríguez-Barrueco,et al.  Neuregulins and Cancer , 2008, Clinical Cancer Research.

[88]  S. Ying,et al.  Intron-mediated RNA interference and microRNA (miRNA). , 2008, Frontiers in bioscience : a journal and virtual library.

[89]  Asli Silahtaroglu,et al.  Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. , 2007, Cancer research.

[90]  Leonard D. Goldstein,et al.  MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype , 2007, Genome Biology.

[91]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[92]  D. Baltimore,et al.  NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[93]  C. Benz,et al.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies , 2006, Molecular Cancer.

[94]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[95]  Jin-Wu Nam,et al.  Genomics of microRNA. , 2006, Trends in genetics : TIG.

[96]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[97]  Anna Janowska-Wieczorek,et al.  Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer , 2005, International journal of cancer.

[98]  P. Pandolfi.  Breast cancer--loss of PTEN predicts resistance to treatment. , 2004, The New England journal of medicine.

[99]  S. Elledge,et al.  Inhibition of cyclin-dependent kinases by p21. , 1995, Molecular biology of the cell.